2025-11-30 - Analysis Report
Okay, let's break down the analysis of Natera Inc. (NTRA) based on the provided data.

**0) Simple Numbers & Analysis**

*   **Cumulative Return (NTRA):** 145.83%
*   **Cumulative Return (VOO - S&P 500):** 102.18%
*   **Current Stock Price:** \$238.81
*   **5-day SMA:** 236.33
*   **20-day SMA:** 213.33
*   **60-day SMA:** 188.06
*   **RSI:** 82.12
*   **Expected Return:** -48.0%
*   **Analyst Consensus:** Strong Buy (Mean: 1.47)
*   **Target Price (Average):** \$234.68
*   **Most Recent EPS:** -0.64
*   **Most Recent Revenue:** \$0.59B

**1) Return Rate Comparison & Analysis**

*   **Company Overview:** Natera Inc. is a diagnostics company specializing in cell-free DNA testing.
*   **Return Rate Comparison:** NTRA's cumulative return (145.83%) significantly outperforms the S&P 500 (VOO) cumulative return (102.18%).
*   **Divergence Analysis:** The divergence between NTRA and VOO is currently 42.0, with a relative divergence of 49.7. This means the current divergence is nearly in the middle of its historical range (between min -89.0 and max 174.4).
*   **Alpha, Beta Analysis:**

    | Year       | CAGR   | MDD  | Alpha   | Beta  | Cap(B) |
    |------------|--------|------|---------|-------|--------|
    | 2015-2017  | -10.0% | 70.1% | -34.0%  | -0.2  | 1.2    |
    | 2016-2018  | 22.0%  | 80.0% | 6.0%    | 0.1   | 1.9    |
    | 2017-2019  | 50.0%  | 80.0% | 28.0%   | 1.0   | 4.7    |
    | 2018-2020  | 186.0% | 80.5% | 163.0%  | 1.1   | 13.7   |
    | 2019-2021  | 96.0%  | 80.5% | 49.0%   | 1.6   | 12.9   |
    | 2020-2022  | -77.0% | 80.5% | -76.0%  | 0.1   | 5.5    |
    | 2021-2023  | -194.0%| 76.6% | -195.0% | -1.1  | 8.7    |
    | 2022-2024  | 8.0%   | 76.6% | -13.0%  | -1.2  | 21.9   |
    | 2023-2025  | 173.0% | 76.6% | 106.0%  | 0.1   | 33.0   |

    *   **CAGR:** The Compound Annual Growth Rate shows significant volatility, ranging from -194% to +186%.
    *   **MDD:** The Maximum Drawdown is consistently high, indicating significant risk.
    *   **Alpha:**  Alpha measures the excess return relative to the benchmark.  The large positive alpha during some periods (e.g., 2018-2020) indicates strong outperformance. Conversely, large negative alpha values (e.g., 2021-2023) indicate significant underperformance.
    *   **Beta:** Beta measures the stock's volatility relative to the market. Beta values near 1 suggest volatility similar to the market, while values greater than 1 indicate higher volatility. The beta changes greatly over time, with values as high as 1.6 and as low as -1.2.

**2) Recent Stock Price Fluctuations**

*   **Price Movement:** The current price of \$238.81 is above all three SMAs (5-day, 20-day, 60-day), suggesting a recent uptrend.
*   **SMA Analysis:** The 5-day SMA is above the 20-day SMA, which is above the 60-day SMA, further confirming the upward trend.
*   **Last-market:** {'price': 238.81, 'previousClose': 237.12, 'change': 0.71} reflects a very slight increase in the last market.

**3) RSI, PPO, and Expected Return Analysis**

*   **MRI:** The Market Risk Indicator of 0.9 suggests "High Investment Recommended".
*   **RSI:** The RSI of 82.12 indicates that the stock is overbought, which could signal a potential pullback.
*   **PPO:** The PPO (Percentage Price Oscillator) of 0.9346 suggests positive momentum.
*   **Hybrid Signal:** "cash\_0% Buy 100% of cash" suggests a strong buy signal, likely driven by the MRI.
*   **Recent Relative Divergence Change:**  The short-term increase in relative divergence (+11.7) suggests a short-term upward trend.
*   **Expected Return:** The very low expected return of -48.0% is a significant concern.

**4) Recent News & Significant Events**

*   **Q3 Earnings Beat:** Natera reported a Q3 loss but beat revenue estimates (Yahoo Finance). This is generally a positive short-term signal.
*   **Stock Up 3%:** Quiver Quantitative notes the stock increase, implying positive market sentiment.
*   **OncoEMR Integration:** The OncoEMR integration (Stock Titan) is a positive development that expands Natera's reach.
*   **Director Stock Sale:** A director's multi-million dollar stock sale (TipRanks) is a concerning signal that could indicate insider pessimism.
*   **Cancer Testing Stock Potential:** Trefis analysis suggests significant upside potential, but this report is from September and may be outdated.
*   **Flatiron Partnership:** The Flatiron partnership (simplywall.st) could provide a competitive edge in OncoEMR integration.

**4-2) Analyst Opinions**

*   **Consensus:** The "Strong Buy" consensus with a mean of 1.47 is very bullish.
*   **Target Price:** The average target price of \$234.68 is slightly *below* the current price, suggesting limited immediate upside from the analyst perspective, especially given the Strong Buy rating.
*   **Recent Rating Changes:** No recent rating changes were provided.

**5) Recent Earnings Analysis**

| Date       | EPS    | Revenue        |
|------------|--------|----------------|
| 2025-11-07 | -0.64  | 0.59 B\$       |
| 2025-08-08 | -0.74  | 0.55 B\$       |
| 2025-05-09 | -0.5   | 0.50 B\$       |
| 2024-11-12 | -0.26  | 0.44 B\$       |
| 2025-11-07 | -0.26 | 0.44 B\$ |

*   **EPS Trend:** Natera is consistently losing money, although the EPS appears to be trending closer to zero.
*   **Revenue Trend:** Revenue is growing steadily, which is a positive sign. The latest earnings results beat the consensus because of the higher revenue figures.

**6) Financial Information**

Revenue and Profitability:

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30   | \$0.59B | 64.91%        |
| 2025-06-30   | \$0.55B | 63.41%        |
| 2025-03-31   | \$0.50B | 63.12%        |
| 2024-12-31   | \$0.48B | 62.94%        |
| 2024-09-30   | \$0.44B | 61.79%        |

Capital and Profitability:

| Quarter      | Equity  | ROE     |
|--------------|---------|---------|
| 2025-09-30   | \$1.25B | -6.99%  |
| 2025-06-30   | \$1.25B | -8.10%  |
| 2025-03-31   | \$1.24B | -5.40%  |
| 2024-12-31   | \$1.20B | -4.50%  |
| 2024-09-30   | \$0.88B | -3.60%  |

*   **Revenue Growth:** Revenue is increasing consistently, demonstrating growth in the company's core business.
*   **Profit Margin:** The profit margin is high (above 60%) and increasing, indicating that the company is becoming more efficient at generating profits from its revenue.
*   **Equity:** Equity is also increasing, suggesting that the company is growing its asset base.
*   **ROE:** The negative Return on Equity reflects the company's current unprofitability, but the trend shows it slowly moving up towards zero.

**7) Comprehensive Analysis (Summary)**

Natera Inc. (NTRA) presents a mixed picture.

*   **Positives:**
    *   Strong historical outperformance relative to the S&P 500.
    *   Recent revenue growth and high profit margins.
    *   "Strong Buy" analyst consensus, despite the price currently trading above the mean target price.
    *   Positive momentum indicated by PPO and recent stock price movement above SMAs.
    *   Strategic initiatives like OncoEMR integration and the Flatiron partnership.
    *   High MRI suggesting investment at this level is recommended

*   **Negatives:**
    *   High historical volatility (MDD).
    *   RSI indicates the stock may be overbought.
    *   Consistent unprofitability (negative EPS and ROE).
    *   The very low Expected Return of -48.0% is a significant concern and does not align with the high MRI.
    *   A director's recent stock sale raises concerns about insider confidence.

*   **Overall:**

Natera appears to be a high-growth, high-risk stock. While recent revenue and profit margin improvements are encouraging, the company's unprofitability, high volatility, and the director's stock sale should give investors pause. The "Strong Buy" consensus seems overly optimistic considering the financial data. The negative expected return is particularly alarming.

The stock is trading above its average analyst target price. Investors should consider that the stock may be overbought and could be due for a pullback. Given the significant divergence between the positive MRI recommendation and the negative Expected Return, further investigation is warranted to understand the discrepancy. Proceed with caution.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.